Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...

Amgen's phase 2 data disappointed, but its obesity pipeline still holds potential. See why AMGN stock is appealing even without the full upside from MariTide.

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen released promising results from its Phase 2 trial, but the data led to a significant decline in its stock price as Wall ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

In a report released yesterday, Charlie CY Yang from Bank of America Securities maintained a Hold rating on Amgen (AMGN – Research Report), ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...